Page 1

Arecor Therapeutics plc ( " Arecor ” , the “ Company ” or the “ Group ” ) INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 Positive results from Phase I clinical trial for AT278 ultra - concentrated ultra - rapid acting insulin candidate for diabetes Three new partnership agreements Successful £ 20 million AIM IPO Cambridge , UK , 23 September 2021 : Arecor Therapeutics plc ( AIM : AREC ) , a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives , today announces its interim results for the six months ended 30 June 2021 . Sarah Howell , Chief Executive Officer of Arecor , said : " We have made tremendous progress across the business during the first six months of the year with our successful IPO on AIM and very successful Phase I clinical results for AT278 being key highlights . Earlier this week , we announced positive results from the Phase I clinical trial for our ultra - concentrated ultra - rapid acting insulin , AT278 , the second product in our diabetes franchise . This follows the positive results of the Phase I clinical trial for AT247 , our ultra - rapid acting insulin , and positions Arecor with a combination of rapid concentrated and ultra - rapid insulins to advance diabetes treatment . In addition , our new partnership agreements with Lilly and Par , and most recently with Intas Pharmaceuticals , further demonstrate the strength and breadth of our Arestat ™ platform . With the £ 20 million raised , we are now well - placed to advance our proprietary pipeline with further clinical trials for our lead products planned in the coming year , including the expected completion of the US Phase I clinical trial for AT247 . " Operational Highlights ( including post - period events ) : • • • Positive results from Phase I clinical trial for AT278 , an ultra - concentrated ultra - rapid acting insulin , demonstrating significantly early accelerated PK / PD profile compared to market leading comparator , NovoRapidⓇ Positive Phase I clinical data of AT247 presented at ATTD , the leading international diabetes conference Received FDA clearance of IND application for AT247 , an ultra - rapid acting insulin , paving the way for the US clinical trial Signed three new partnership agreements with Eli Lilly and Company ( ‘ Lilly ' ) , Par Sterile Products ( ' Par ' ) and Intas Pharmaceuticals ( ' Intas ' ) • Awarded £ 2.8 million Innovate UK grant to support Phase II development of AT247 • Grant of US patent as part of a global patent portfolio underpinning the Arestat ™ platform